ArticleJournal of advanced research2026
Development and validation of an interpretable machine learning model using routine laboratory biomarkers to stratify severe pneumonia risk in young children.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Developing an explainable machine learning model using body composition to predict cardiovascular mortality in initial dialysis patients: a multicenter study.Frontiers in physiology · 2026Article
- The "two-hit" storm: a hyper-inflammatory endotype in pediatric long COVID and its role in the severity of secondary bacterial pneumonia-a mechanistic review and clinical implications.Frontiers in public health · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSevere pneumonia is a leading infectious cause of mortality in children under 5 years globally. Early identification of high-risk cases remains challenging due to the lack of reliable stratification tools.
objectivesThis study aimed to develop an interpretable machine learning (IML) model using routine laboratory biomarkers for simultaneous diagnosis of severe pneumonia at admission and prediction of progression risk during hospitalization.
methodsThis retrospective cohort study analyzed 85,886 children with pneumonia from a Chinese tertiary hospital (2013-2023). Two matched cohorts were established: Cohort I (n = 7,132) for admission diagnosis, and Cohort II (n = 1,064) for progression prediction. Fifty-seven laboratory parameters collected within 24 h of admission were extracted from electronic health records. Nine machine learning (ML) algorithms underwent systematic evaluation. Model performance was assessed using the area under the receiver-operating-characteristic curve (AUC), among other metrics. Model interpretability was achieved via SHapley Additive exPlanations (SHAP) analysis.
resultsWe evaluated the performance of nine machine learning algorithms and the CatBoost model incorporating 11 laboratory features demonstrated superior performance (AUC: 0.879 for admission diagnosis; 0.839 for progression prediction). Key feature thresholds were optimized using Youden's index (e.g., chloride ≤ 99 mmol/L). A real-time web application with case-level interpretability was deployed.
conclusionThis interpretable CatBoost model accurately stratifies pediatric severe pneumonia risk using routine laboratory data. Clinical implementation via the web tool may facilitate early intervention in resource-limited settings, though extensive external validation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.